NT-219 is under clinical development by Purple Biotech and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NT-219’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NT-219 overview

NT-219 is under development for the treatment of metastatic solid tumors including Gastroesophageal (GE) Junction Carcinomas, pancreatic cancer, breast cancer, colorectal adenocarcinoma recurrent head and neck cutaneous squamous cell carcinoma (HNCSCC),  The drug candidate acts by targeting insulin receptor substrate 1/2 and STAT3. NT-219 is a new chemical entity. It is administered through parenteral roue.

It was also under development for the treatment of neurodegenerative disorders including Alzheimer's disease, uterine adenosarcoma, sarcoma and non-small cell lung cancer, anaplastic thyroid cancer, prostate cancer, metastatic melanoma, ovarian cancer, esophagus cancer, Parkinson's disease and Huntington's disease.

Purple Biotech overview

Purple Biotech is a clinical-stage biotechnology company that develops first-in-class medication that helps surmount immune evasion and drug resistance by tumors. Its oncology pipeline includes NT219, CM24, and IM1240. NT219 (a dual inhibitor) is a small molecule for the treatment of solid tumors and is used in an increased dose together with cetuximab to treat recurrent and metastatic squamous cell carcinoma of the neck and head. CM24 is a humanized monoclonal antibody that blocks CEACAM1 (an immune checkpoint protein), which aids tumor immune evasion and survival by tumors through multiple pathways. The company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors for the treatment of pancreatic ductal adenocarcinoma. In collaboration with Bristol Myers Squibb, the company is evaluating the combination of CM24 with the PD-1 inhibitor nivolumab, besides chemotherapy. IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both NK cells and T cells to demonstrate a robust, localized immune response within the tumor microenvironment. Purple Biotech is headquartered in Rehovot, Israel.

For a complete picture of NT-219’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.